HER3 targeting antibody drug conjugate - Biotheus
Latest Information Update: 02 Feb 2024
At a glance
- Originator Biotheus
- Class Antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 24 Jan 2024 HER3 targeting antibody drug conjugate is available for licensing as of 24 Jan 2024. https://www.biotheus.com/Business_Partnership.html (Biotheus website, January 2024)
- 24 Jan 2024 Early research in Unspecified in China (Parenteral) before January 2024 (Biotheus pipeline, January 2024)